Key result
Drug-eluting stents linked to ~31-point lower 90-day in-stent restenosis versus bare-metal stents in ICAD.
Cohort (n=78)
Open-label
No
Retrospective comparison demonstrates lower complications and restenosis rates with drug-eluting stents in intracranial atherosclerosis, suggesting reevaluation of treatment options.
Introduction Due to several issues with endovascular treatment of intracranial symptomatic atherosclerotic disease (ICAD), international guidelines recommend drug therapy as first-line treatment since almost 10 years. Regardless of this, endovascular ICAD treatment has meanwhile progressed, significantly reducing periprocedural complication rates. However, early in-stent restenosis (ISRS) remains, so far, unchallenged. Cardiologists had been at a similar point in the evolution of cardiac artery stenting and challenged ISRS through drug-eluting stents (DES). Therefore, 90d results and restenosis rates of patients treated with DES versus bare-metal stents (BMS) were compared to determine whether DES could also solve the neurovascular problem. Methods All endovascular ICAD treatments in 2014–2022 at a single institution through DES were retrospectively compared to all BMS-treatments in regards to periprocedural complications and ISR rates. Perioperative procedures and drug regimen were comparable for all patients, follow-up was carried out 90 days after treatment through digital subtraction angiography, clinical status was recorded by a board certified neurologist. Results Fifty-two patients were treated for ICAD with DES, 26 patients received ICAD-treatment with BMS. Patients’ demographics and comorbidities were comparable. The periprocedural and ISR-rates were significantly lower in DES compared to BMS. Discussion The lower periprocedural complication rate may be due to less complexity of the DES system, while lower ISR in the DES group may be connected to reduced endothelium irritation and proliferation through the eluted sirolimus. Conclusion In the population studied, DES achieved equal to better results in comparison to BMS. This study supports a re-evaluation of the role of endovascular ICAD-treatment as first line therapy in the light of the most recent developments on knowledge and techniques.
No takes yet. Share an insight, caveat, or question.
Gottberg et al. (2026) conducted a cohort in Intracranial symptomatic atherosclerotic disease (ICAD) (n=78). Drug-eluting stents (DES) vs. Bare-metal stents (BMS) was evaluated on In-stent restenosis (ISRS) at 90 days (p=<0.001). In patients with drug-refractory intracranial atherosclerotic disease, drug-eluting stents significantly reduced 90-day in-stent restenosis compared to bare-metal stents (3.8% vs 34.6%, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: